Inspira Technologies Facing Nasdaq Delisting Risk Over Market Value Deficiency
Event summary
- Inspira Technologies received a Nasdaq notification on February 19, 2026, for failing to meet the minimum market value of publicly held shares ($35M) requirement.
- The company has until August 18, 2026, to regain compliance by achieving a market value of at least $35M for 10 consecutive business days.
- Inspira's ordinary shares continue to trade on the Nasdaq Capital Market under the symbol 'IINN'.
- The company's INSPIRA™ ART100 system is FDA-cleared for cardiopulmonary bypass in the U.S. and ECMO procedures outside the U.S.
The big picture
Inspira Technologies' compliance issue highlights the challenges faced by small-cap medical device companies in maintaining market value amidst regulatory scrutiny. The situation underscores the importance of sustained investor interest and operational milestones in the competitive life-support and MedTech landscape. The company's ability to navigate this period will be critical for its long-term listing status and growth prospects.
What we're watching
- Market Recovery
- How Inspira Technologies will attempt to boost its market value to avoid delisting, including potential strategic moves or investor outreach.
- Regulatory Compliance
- Whether the company can sustain compliance with Nasdaq's listing requirements beyond the current deficiency.
- Operational Strategy
- The pace at which Inspira Technologies advances its product pipeline, particularly the INSPIRA ART500 and HYLA™, to drive investor confidence.
Related topics